 - Disease characteristics: Patients with indolent subtypes of CD22 B-cell non- Hodgkins lymphoma, including, but not limited to mantle cell lymphoma, follicular lymphoma and Waldenströms macroglobulinemia, are eligible if stage III-IV. if stage III-IV. Patients must have failed at least two or more courses of prior standard chemotherapy andor biologic therapy e.g. Rituxan. Patients with progressive mantle cell lymphoma may be eligible if they have failed one prior standard therapeutic regimen. 